The Feasibility of a Guideline-Directed Medical Therapy Rapid Up-Titration Programme Among Real-World Heart Failure Patients: A Multicentre Observational Study.

Journal: Journal Of Clinical Medicine
Published:
Abstract

Background: The 2023 ESC Heart Failure (HF) Guidelines recommend the rapid up-titration of guideline-directed medical therapy (GDMT) for all patients after HF hospitalisation. Real-world data on the implementation of a rapid up-titration programme (RTP) are scarce.

Methods: We aimed to summarise the primary experiences of a six-week RTP in a multicentre observational study of five cardiology centres, evaluating the GDMT applied and the target doses (TDs) achieved during the RTP. The safety of RTP in relation to exceeding the "safety indicators" used in the STRONG-HF trial and any serious adverse events were observed. Changes in the left ventricular ejection fraction (LVEF) after RTP were evaluated.

Results: Among the 90 consecutive patients (age: 56 [49-63] years, HFrEF: 96%, NT-proBNP at discharge: 1390 [735-2835] pg/mL; continuous variables are presented as median and interquartile ranges, while categorical variables are shown as absolute numbers and percentages, respectively), a remarkable proportion of patients received GDMT at hospital discharge; however, target doses were rarely achieved (RASi: 100%, TD RASi: 11%; βB: 97%, TD βB: 6%; MRA: 99%, TD MRA: 82%; SGLT2i: 98%, TD SGLT2i: 98%; triple therapy [TT: RASi + βB + MRA]: 96%, TD TT: 2%, quadruple therapy [QT: RASi + βB + MRA]: 94%, TD QT: 2%). After the six-week RTP, 100% of the total cohort (TC) were receiving RASi; 99-99-99% were receiving βB, MRA, and SGLT2i medications; and altogether, 98-98% were on TT and QT. In total, 78-78% of the patients received ≥50% of the TDs of TT and QT, while 51-51% of the TC were on TDs of TT and QT. During the RTP, no serious adverse events were observed. Between two and four months after the RTP, 51% of HFrEF patients evolved to the HFimpEF category.

Conclusions: The present multicentre, observational study confirms that RTP is feasible and safe in real-world clinical practice, leading to a remarkably large proportion of patients receiving GDMT by the end of the six-week RTP, resulting in a significant increase in LVEF.

Authors
Fanni Bánfi Bacsárdi, Arnold Ráduly, Attila Borbély, Noémi Nyolczas, Attila Szilágyi, Tamás Gergely, Zsolt Forrai, Judit Papp, Orsolya Rátosi, Tünde Rácz, Krisztina Hati, Ildikó Kocsis, Zoltán Csanádi, Gábor Duray, Péter Andréka, Zsolt Piróth, Balázs Muk
Relevant Conditions

Heart Failure